Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib-Enhanced Conditioning for Haploidentical HCT in Sickle Cell Disease
NCT07252050Phase 2Recruiting
- Sponsor
- Arkansas Children’s Research Institute
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Graft failure, sickle cell disease (SCD), sponsored by Arkansas Children’s Research Institute. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
Graft failuresickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07252050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252050.